AKT1 and Miyoshi myopathy: The efficacy of capivasertib (AZD5363) combined with paclitaxel as a first-line treatment for locally advanced or metastatic TNBC patients is under evaluation in a phase III trial (NCT03997123).403 Afuresertib (GSK2110183) monotherapy showed satisfactory safety and clinical activity against hematological malignancies, including MM.404 Uprosertib (GSK2141795) was used for relapsed or refractory MM either alone or in combination with trametinib in phase I and II clinical trials (NCT01989598, NCT01979523).405 In addition, allosteric AKT inhibitors are represented by MK-2206.